← Leaderboards
Sharon B Cantor
Univ Of Massachusetts Med Sch Worcester
$10,161,991
Attributed
$10,161,991
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,161,991 · 7
By mechanism
R01$10,118,759 · 5
F32$39,232 · 1
R13$4,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Nicholas R Rhind$10,128,647
- Jenna Whalen$226,480
- Nathan Macgilvary$34,348
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightPathway InteractionsCellsDna BiosynthesisDna DamageMalignant NeoplasmsProteinsMutantGenesChemotherapyResponseResistanceBrca1 GeneCancer CellPreventDna RepairDna Replication ForkProteomicsGenomeDefectMutationComplexStressBrca2 Gene
Grant awards (28)
Defining BRCA replication dysfunction in therapy response$401,524
R01 · FY2025 · CA · contact PI
Targeting replication stress avoidance in cancer$462,089
R01 · FY2024 · CA · contact PI
Defining BRCA replication dysfunction in therapy response$443,626
R01 · FY2024 · CA · contact PI
Targeting replication stress avoidance in cancer$452,158
R01 · FY2023 · CA · contact PI
Defining BRCA replication dysfunction in therapy response$544,773
R01 · FY2022 · CA · contact PI
Targeting replication stress avoidance in cancer$455,474
R01 · FY2022 · CA · contact PI
FANCJ dependent pathways in replication stress$356,443
R01 · FY2022 · CA · contact PI
DNA Damage, Mutation and Cancer GRC and GRS$4,000
R13 · FY2022 · CA · contact PI
Defining BRCA replication dysfunction in therapy response$555,892
R01 · FY2021 · CA · contact PI
Targeting replication stress avoidance in cancer$467,554
R01 · FY2021 · CA · contact PI
FANCJ dependent pathways in replication stress$358,746
R01 · FY2021 · CA · contact PI
Defining BRCA replication dysfunction in therapy response$625,979
R01 · FY2020 · CA · contact PI
Targeting replication stress avoidance in cancer$494,159
R01 · FY2020 · CA · contact PI
FANCJ dependent pathways in replication stress$387,989
R01 · FY2020 · CA · contact PI
FANCJ dependent pathways in replication stress$376,348
R01 · FY2019 · CA · contact PI
FANCJ dependent pathways in replication stress$36,850
R01 · FY2019 · CA · contact PI
FANCJ dependent pathways in replication stress$404,864
R01 · FY2018 · CA · contact PI
Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer$347,563
R01 · FY2018 · CA · contact PI
Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer$347,563
R01 · FY2017 · CA · contact PI
Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer$347,563
R01 · FY2016 · CA · contact PI
Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer$347,563
R01 · FY2015 · CA · contact PI
Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer$345,176
R01 · FY2014 · CA · contact PI
BACH1/FANCJ Checkpoint, Recombination, and Chemoresistance$323,863
R01 · FY2011 · CA · contact PI
BACH1/FANCJ Checkpoint, Recombination, and Chemoresistance$308,750
R01 · FY2010 · CA · contact PI
BACH1/FANCJ Checkpoint, Recombination, and Chemoresistance$308,750
R01 · FY2009 · CA · contact PI
BACH1/FANCJ Checkpoint, Recombination, and Chemoresistance$308,750
R01 · FY2008 · CA · contact PI
BACH1/FANCJ Checkpoint, Recombination, and Chemoresistance$308,750
R01 · FY2007 · CA · contact PI
FUNCTIONAL ANALYSIS OF BRCA1$39,232
F32 · FY2000 · CA